Daily Digest: Cannabinoids and Fatty Liver Disease Promise Amid Regulatory Gaps — March 06, 2026
This digest reviews cannabinoids and liver disease research with a focus on emerging preclinical evidence for fatty liver disease. The research highlights promising mechanisms but also regulatory gaps. Clinicians remain cautious pending robust clinical…
Cannabis Compounds Exhibit Potential in Combatting Fatty Liver Disease
Emerging cannabis compounds fatty liver disease research suggests potential metabolic benefits in reducing hepatic steatosis. This early-stage evidence highlights therapeutic possibilities beyond lifestyle changes. Further human trials are needed to…
Daily Digest: Last 6 Hours: Cognitive Safety, Liver Disease Breakthroughs, and the Drug Testing Problem That Won’t Go Away — March 06, 2026
This digest highlights cannabis cognitive aging research alongside promising cannabinoid liver disease studies. It also addresses ongoing drug testing challenges. These insights reflect the evolving landscape of cannabis medicine.
Daily Digest: Last 48 Hours: Cognitive Safety, End-of-Life Access, and the Impairment Testing Problem — March 06, 2026
This daily digest highlights the impairment testing problem cannabis presents in clinical and policy contexts. It also covers cognitive safety and end-of-life access issues. The focus on impairment testing problem cannabis is crucial for advancing…
Natural Approaches to Managing Chronic Inflammation with Cannabinoids
The endocannabinoid system chronic inflammation interaction is a promising area for therapeutic exploration. Phytocannabinoids like CBD and THC modulate immune responses relevant to chronic inflammation. Understanding this system can guide safer, more…
Natural Neuroprotection: Exploring Non-Psychoactive Cannabinoids
Non-psychoactive cannabinoids neuroprotection offers promising avenues for neurological health. These compounds interact with the endocannabinoid system to modulate inflammation and oxidative stress. While preclinical data is strong, clinical evidence…
Cannabis compounds show promise in fighting fatty liver disease, scientists say – AZERTAC
WHY IT MATTERS: Patients with fatty liver disease or metabolic syndrome may eventually have access to cannabinoid-based therapies as an adjunct treatment option, but only after human clinical trials confirm the safety and efficacy signals seen in early…
Study Finds No Link Between Lifetime Cannabis Use and Cognitive Decline in Older Adults
A recent study found no link between lifetime cannabis use cognitive decline in older adults. This evidence suggests that past cannabis exposure does not increase dementia risk. Clinicians can use these findings to inform patient discussions about…
Daily Digest: Cognitive Safety, End-of-Life Cannabis Access, and Regulatory Challenges — March 06, 2026
End-of-life cannabis access remains a critical issue for patients and healthcare providers. This digest highlights regulatory gaps and hospital policies impacting terminally ill patients. Cognitive safety in older adults using cannabis is also examined…
Daily Digest: Last 9 Hours: Cognitive Safety Data, End-of-Life Access, and Regulatory Friction — March 05, 2026
This digest highlights recent research on cognitive safety in older adults using cannabis, addressing dementia risk and clinical implications. It also covers advances in end-of-life cannabis access and ongoing regulatory friction. These insights provide…